Table 1. Selected trials targeting... | American Society of Hematology

Table 1.

Selected trials targeting inflammation in MDS and CH

Class	Agent	Trial name	Phase	Population	Status	Identifier
TGF-β pathway	Luspatercept	PACE-MDS (24)	2	LR-MDS	Completed	NCT01749514
TGF-β pathway	Luspatercept vs placebo	MEDALIST (25)	3	LR-MDS-RS	Completed	NCT02631070
TGF-β pathway	Luspatercept vs epoetin alfa	COMMANDS	3	LR-MDS	Recruiting	NCT03682536
TGF-β pathway	Luspatercept + lenalidomide	—	1/2	LR-MDS	Recruiting	NCT04539236
TGF-β pathway	Galunisertib	—	2	LR-MDS	Completed	NCT02008318
TGF-β pathway	Vactosertib	—	1/2	LR-MDS	Completed	NCT03074006
TIM-3 pathway TGF-β pathway IL-1β inhibitor	Sabatolimab NIS793 Canakinumab	—	1b	LR-MDS	Recruiting	NCT04810611
IL-1β inhibitor	Canakinumab	—	2	LR-MDS or MDS/MPN	Recruiting	NCT05237713
IL-8 inhibitor	BMS-986253 ± PO decitabine and cedazuridine	—	1/2	HR-MDS with prior HMA therapy or LR-MDS with cytopenias	Not yet Recruiting	NCT05148234
CXCR1 and CXCR2 inhibitor	SX-682	—	1	MDS with disease progression or prior therapy intolerance	Recruiting	NCT04245397
TLR2 inhibitor	Tomaralimab	—	1/2	LR-MDS with prior HMA	Completed	NCT02363491
IRAK4 inhibitor	Emavusertib (CA-4948)	CURIS	1	HR-MDS and AML	Active	NCT04278768
IRAK4 inhibitor	Emavusertib (CA-4948)	LUCAS	2	LR-MDS	Recruiting	NCT05178342

Class	Agent	Trial name	Phase	Population	Status	Identifier
TGF-β pathway	Luspatercept	PACE-MDS (24)	2	LR-MDS	Completed	NCT01749514
TGF-β pathway	Luspatercept vs placebo	MEDALIST (25)	3	LR-MDS-RS	Completed	NCT02631070
TGF-β pathway	Luspatercept vs epoetin alfa	COMMANDS	3	LR-MDS	Recruiting	NCT03682536
TGF-β pathway	Luspatercept + lenalidomide	—	1/2	LR-MDS	Recruiting	NCT04539236
TGF-β pathway	Galunisertib	—	2	LR-MDS	Completed	NCT02008318
TGF-β pathway	Vactosertib	—	1/2	LR-MDS	Completed	NCT03074006
TIM-3 pathway TGF-β pathway IL-1β inhibitor	Sabatolimab NIS793 Canakinumab	—	1b	LR-MDS	Recruiting	NCT04810611
IL-1β inhibitor	Canakinumab	—	2	LR-MDS or MDS/MPN	Recruiting	NCT05237713
IL-8 inhibitor	BMS-986253 ± PO decitabine and cedazuridine	—	1/2	HR-MDS with prior HMA therapy or LR-MDS with cytopenias	Not yet Recruiting	NCT05148234
CXCR1 and CXCR2 inhibitor	SX-682	—	1	MDS with disease progression or prior therapy intolerance	Recruiting	NCT04245397
TLR2 inhibitor	Tomaralimab	—	1/2	LR-MDS with prior HMA	Completed	NCT02363491
IRAK4 inhibitor	Emavusertib (CA-4948)	CURIS	1	HR-MDS and AML	Active	NCT04278768
IRAK4 inhibitor	Emavusertib (CA-4948)	LUCAS	2	LR-MDS	Recruiting	NCT05178342

AML, acute myelogenous leukemia; HMA, hypomethylating agent; MPN, myeloproliferative neoplasms; TBD, to be determined; TLR2, Toll-like receptor 2.